Citing the significant quality of life benefits that oral chemotherapy drugs can provide over intravenously (IV) administered chemotherapy, Maryland’s cancer community, patient advocacy representatives and patients themselves called on the state legislature this week to pass key legislation that would ensure Maryland’s cancer patients are able to access their prescribed chemotherapy regimen of choice.

IV chemotherapy can lead to side effects including pain, hair loss, nausea, vomiting, and anemia, and can lead to added costs and logistical issues as patients must travel to cancer care facilities for treatment. Although oral chemotherapy drugs taken at home often result in fewer side effects, many health insurance plans’ coverage of orally administered chemotherapy is prohibitive due to higher copays, expensive deductibles or restrictive coverage limits.

“Oral chemotherapy drugs can often provide substantially greater comfort and convenience than IV administered chemotherapy, and Maryland’s cancer patients should have access to the treatments they prefer,” said Nancy Davenport-Ennis, founder and CEO of the National Patient Advocate Foundation (NPAF) and the Patient Advocate Foundation (PAF).

“We urge Maryland’s legislature to create parity in coverage and help individuals fighting cancer access the chemotherapy treatment of their choice without cost being an unrealistic barrier.”

The Kathleen A. Mathias Chemotherapy Parity Act of 2012 (Senate Bill 179) would prohibit insurers, nonprofit health service plans, and  health maintenance organizations (HMOs) from covering orally administered cancer chemotherapy on terms that are less favorable than coverage for IV administered cancer chemotherapy.

The bill is named in honor of the late Kathy Mathias, wife of Sen. Jim Mathias (D-38), who lost her 14-year battle with cancer last August. The legislation currently has 26 cosponsors in the Senate and will be heard before the Maryland House Health and Government Operations Committee on February 9.

In testimony this week before the Maryland Senate Finance Committee, Larry L. Lanier, NPAF Vice President of State Government Affairs, noted that parity in chemotherapy drug coverage remains an important issue for patients, with many contacting PAF on a regular basis in need of assistance to cover the cost of oral chemotherapy medications.

Additional testimony was provided by representatives from The Maryland/District of Columbia Society of Clinical Oncology, the Maryland State Medical Society (MedChi), the Leukemia and Lymphoma Society (LLS), additional Maryland-based advocates, and patients who would benefit from the passage of this legislation.

“Senate Bill 179 would help Maryland’s cancer patients receive the prescribed chemotherapy treatment of their choice, and could help many individuals experience fewer side effects, maintain their jobs, and spend more time at home with their loved ones during a very challenging time,” said Mary Edwards, a registered nurse from Owings Mills who has worked with numerous cancer patients over the years.

“We hope that our lawmakers will join the 15 other states and the District of Columbia in passing similar legislation, and help improve Maryland cancer patients’ physical and emotional well-being while providing them with the treatment choices they deserve.”

The article State Legislature Urged to Create Parity in Coverage for Cancer Drugs appeared first on The Toonari Post - News, Powered by the People!.

In 1962, St. Jude Children’s Research Hospital opened its doors amid an emotionally charged debate regarding how to treat childhood cancer. At that time, few children with the most common form of childhood cancer survived, and many physicians believed treatment was futile.

St. Jude physicians and researchers took a radically different approach, and these efforts proved pivotal in changing the way the world treats childhood cancer. St. Jude is recognized for playing a significant role in improving overall survival rates for childhood cancer, which have increased from 20 percent in 1962 to 80 percent today.

In recognition of this impact over the past 50 years, Tennessee Gov. Bill Haslam declared February “St. Jude Month” in the state of Tennessee. Founded by the late entertainer Danny Thomas, the hospital opened February 4, 1962.

“In the nearly four decades I’ve been at St. Jude, I’ve had the privilege of watching the organization grow from one star-shaped building to a sprawling campus of about 2.5 million square feet of research, clinical and administrative space,” said Dr. William E. Evans, St. Jude director and CEO.

“When I started, there were a few hundred people on staff. Now we have more than 3,700 employees. Driven by our patients, and thanks to our employees, our colleagues at ALSAC and the public support they generate, St. Jude will only continue to grow and flourish in the years to come.”

The history of St. Jude is marked with milestones in the treatment of pediatric cancer and other childhood illnesses. In 1971, St. Jude investigators showed that the combination of chemotherapy and radiation cured at least half of all children with acute lymphoblastic leukemia (ALL).

The most common form of childhood cancer, ALL, was previously considered almost universally fatal. Today, St. Jude patients with ALL have a 94 percent survival rate. In 1984, a St. Jude patient with sickle cell disease was the first to be cured with a bone marrow transplant.

St. Jude is currently engaged in the largest effort in the world to do whole genome sequencing of pediatric cancer tumors. The St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project collaboration has already produced significant new findings related to aggressive forms of pediatric leukemia, eye tumors and brain tumors.

“St. Jude has a legacy of taking on the toughest of pediatric cancer questions, and that focus won’t change,” said James R. Downing, M.D., scientific director and deputy director at St. Jude. “We’re uniquely positioned as an institution to move research and treatment ahead. From the genetic data we collect from the genome project, we’re creating the foundation of knowledge to deliver the next decades’ childhood cancer discoveries and treatments.”

Throughout its five decades, St. Jude research has included work in cancer biology and genomics, pharmacogenomics, gene therapy, bone marrow transplant, drug discovery, radiation treatment, blood diseases and infectious diseases, integrated into a long series of innovative clinical trials.

According to Joseph Laver, M.D., St. Jude clinical director, “the unsurpassed family-centered care that is provided at St. Jude stems from the multidisciplinary team approach that has been a hallmark of St. Jude since the doors opened in 1962.”

“Looking toward the future, St. Jude is a national resource with a global mission and will continue to enhance its leadership as a resource for children with cancer and other catastrophic diseases,” Evans said. “Even though we’ve grown significantly, our mission has never wavered.

We’ve created a collaborative culture whose team members demonstrate unceasing compassion for our patients and families, innovation in our treatment and research, and quality in everything we do.”

Image Courtesy of   https://www.facebook.com/stjude

The article St. Jude Children’s Research Hospital Celebrates 50 Years appeared first on The Toonari Post - News, Powered by the People!.

A cancerous tumor was discovered in Luiz Inacio da Silva’s larynx on Saturday. Hugo Chavez, the president of Venezuela, is familiar with the health crisis that Silva, the former Brazilian leader, currently faces. Chavez has had problems with cancer in the past; he has been recovering from chemotherapy and a previous surgery in June, where a malignant tumor was removed from his pelvic region.

Chavez sent a message of solidarity to the former Brazilian president in response to his diagnosis on Sunday and expressed hope for a speedy recovery from the chemotherapy Silva would soon be undergoing. Silva is considered to be in good condition and his chemotherapy and treatment will begin on an outpatient basis.

His diagnosis undermined speculation that he would be running for president again in 2014. During his previous presidential reign, Silva was responsible for the unemployment rate dropping to a record low, cutting the country’s inflation rate by more than half, and bringing up 21 million Brazilians from poverty. He was the most popular Brazilian president ever and served two presidential terms.

Though he stepped down as president, Silva still participates in politics and is the honorary head of the Worker’s Party. His successor, Dilma Rousseff, continues to consult him over political matters. She, too, was treated for cancer in 2009. Doctors informed Finance Minister Guido Mantega that Silva’s cancer was caught in its early stages.

It is possible for throat cancer to be cured in 90 percent of the people diagnosed with it, as long as it is caught early. Smoking and excessively drinking increase the risk of throat cancer. Silva has admitted to smoking in the past. If the cancer pervades into the lymph nodes and surrounding tissues, only 60 percent of patients can be cured.

Rousseff is confident that Silva will make a complete recovery. She survived having lymphoma herself. Silva’s tumor is not large, according to Artur Katz, the oncologist treating Silva. It measures between two and three centimeters. Chavez commented that he will be praying for Silva’s recovery and will closely follow his medical situation, just as Silva did when Chavez was battling cancer.

Chavez claims to be free of cancer now, but a Venezuelan doctor who treated him in the past insists he only has a couple of years to live. The doctor has since fled the country out of fear for his life, and Chavez denies his claims and denounces him as a liar. Silva’s physician, Dr. Roberto Kalil, says that the Brazilian leader is meeting this challenge with a positive attitude.

“He’s very calm. Obviously, at first, there was anxiety, a shock. He arrived in excellent spirits, in his usual way, extremely confident,” said Kalil. It will take around 40 days to observe how Silva’s tumor will respond to chemotherapy.

Image Courtesy of   http://www.flickr.com/photos/worldeconomicforum/

The article Hugo Chavez Sends Solidarity to Lula da Silva appeared first on The Toonari Post - News, Powered by the People!.